Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | JVM-2 is a human mantle cell lymphoma (MCL) cell line derived from the peripheral blood of a 63-year-old female patient presenting with the leukemic phase of the disease. JVM-2 cells exhibit a lymphoblast-like morphology and grow primarily in suspension or as loose aggregates. Genetically, the cell line harbors the characteristic t(11;14)(q13;q32) chromosomal translocation, which juxtaposes the *CCND1* gene with the immunoglobulin heavy chain locus, resulting in the overexpression of cyclin D1. JVM-2 is unique among MCL models because it carries wild-type TP53 and is EBV-negative, making it a valuable model for studying B-cell lymphoproliferative disorders with functional TP53. Due to its stable growth characteristics and distinct molecular phenotype, JVM-2 is widely used to investigate the mechanisms of cyclin D1-mediated tumorigenesis, study B-cell receptor signaling pathways, evaluate targeted therapies such as BTK inhibitors, and conduct high-throughput drug screening. |
| Tissue | Peripheral blood / Bone marrow |
| Disease | Mantle Cell Lymphoma (MCL); Prolymphocytic Leukemia |
| Morphology | Lymphoblast-like |
| Gender | Female |
| Age | 63 years |
| Product Format | Frozen |
| Growth Mode | Suspension |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Research on the pathogenesis of mantle cell lymphoma (MCL) and the cyclin D1 signaling pathway; 2. Study on the response of TP53 wild-type B-cell malignancies to targeted therapies; 3. In vitro screening of BTK inhibitors, BCL-2 inhibitors, and novel chemotherapeutic agents; 4. Functional genomic analysis, target validation, and signal transduction profiling. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Karyotype | Aneuploid |
| Tumorigenic | Yes, forms tumors in immunocompromised mice |
| Genetic Profile | t(11;14)(q13;q32) translocation (CCND1/IGH fusion); CCND1 overexpression; TP53 wild-type |
| Expression Markers | Cyclin D1 positive; CD19 positive; CD20 positive; CD23 positive; CD5 weak/positive; surface Ig (IgM/IgD) positive |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Maintain the culture by adding fresh medium or replacing the medium. 2. Establish the culture by centrifuging (1,000 rpm, 5 minutes) and resuspending the cells (at a density of 2 × 10⁵ to 4 × 10⁵ viable cells/mL). 3. Do not allow the cell concentration to exceed 1.5 × 10⁶ cells/mL. 4. Gently resuspend the cells to prepare a single-cell suspension before subculturing into a new culture vessel. |
| Medium Renewal | Every 2 to 3 days |
| Subcultivation Ratio | Maintain cell density between 2 × 10⁵ and 1.5 × 10⁶ cells/mL (split ratio approximately 1:2 to 1:4) |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% to 10% (v/v) DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RO02654 | Cas9 Stable Cell Line - JVM2 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.